Robuvit,
does it really help with Reduction of oxidative fatigue, resilience, and healthy aging?
research showsSmall human studies of Robuvit 300 mg/day have reported improvements in fatigue questionnaires, postoperative recovery, and oxidative markers. Healthy-volunteer evidence includes an uncontrolled pilot of only 20 participants, and the surgical RCT included 66 participants; studies were linked to the branded-ingredient manufacturer. Subjective and oxidative surrogate outcomes cannot establish broad healthy aging, so the grade is C.
ads claimClaims of 'cellular energy,' 'fast recovery,' 'oxidative-fatigue relief,' and 'healthy aging' expand questionnaires and laboratory values from small selected groups into long-term function and lifespan. Healthy aging itself has not been tested as a clinical outcome.
Useful facts when choosing a product
- Robuvit is a standardized branded extract of French Quercus robur wood; South Korean consumers mainly encounter imported or cross-border products.
- Major human studies used 300 mg/day for four to eight weeks.
- Other oak extracts or polyphenol products are not interchangeable with the Robuvit evidence.
Chamgap Semantic Classification Code
Candidate index · review held
S.robuvit-french-oak-wood-extract.UNK.oxidative-fatigue-resilience-and-healthy-aging.reduce.placeboSupplements and nutraceuticals > Robuvit French oak wood extract > Unknown > oxidative fatigue, resilience, and healthy aging > Reduction claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The uncontrolled Horvathova 2014 study in 20 participants measured oxidized proteins, lipid peroxidation, and antioxidant enzymes over four weeks. Országhová 2015 assessed subjective activation scores in a similarly small healthy-volunteer pilot. Ferianec 2020 randomized 66 women after hysterectomy and assessed eight-week recovery questionnaires and oxidative markers, with manufacturer funding and product supply. Chronic-fatigue data came from a registry pilot rather than a large independent randomized trial.
Why this is classified as C (45)
Small manufacturer-linked studies of one branded ingredient, subjective and oxidative surrogate outcomes, and no broad aging endpoint result in C with 45 points.
Counterpoint. A short-term adjunctive effect on fatigue or recovery remains possible, but large independent RCTs are needed.
Rejudgment record. New verdict — Small manufacturer-linked branded-ingredient studies using fatigue questionnaires and oxidative surrogates cannot establish healthy aging, limiting the grade to C
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduction of oxidative fatigue | C | The signal comes from fatigue questionnaires and oxidative surrogates in small manufacturer-linked studies. |
| Improved recovery | C | A 66-person pilot RCT after hysterectomy cannot establish general resilience. |
| Healthy aging | ? | No study directly measured healthspan, functional decline, or disease incidence. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Horvathova M et al. 2014 | Uncontrolled before-and-after pilot | 20 | Linked to the branded ingredient | Oxidized proteins, lipid peroxidation, SOD, CAT, and total antioxidant capacity | Some oxidative and antioxidant markers improved after 300 mg/day for four weeks; there was no control group. | Supportive |
| Országhová Z et al. 2015 | Uncontrolled healthy-volunteer pilot | 20 | Sponsored by Horphag with an employee author | Subjective activation and deactivation questionnaire | Some subjective energy scores improved after four weeks; there was no blinding or placebo control. | Supportive |
| Ferianec V et al. 2020 | Randomized, double-blind, placebo-controlled pilot | 66 | Horphag grant and product supply | Recovery and fatigue questionnaires plus oxidative-stress markers | Signals of improved eight-week recovery and selected markers in a small, specific surgical population. | Key |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-17).
Final verification and publication gate: Codex · Evidence date: 2026-07-17 · Corrections: none
Cite this verdict
[Chamgap] Robuvit x reduction of oxidative fatigue, resilience, and healthy aging — Evidence Grade C·45. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/antioxidant-aging/robuvit-fatigue-recovery-healthy-aging/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.